BioSpace » Biotechnology Industry News
182 FOLLOWERS
Read breaking news on the biotechnology industry from BioSpace, the Home of the Life Sciences Industry.
BioSpace » Biotechnology Industry News
2d ago
GSK’s antibiotic eliminated the bacterial cause of gonorrhea in 92.6% of patients in a Phase III study, while its Shingrix vaccine’s efficacy in shingles remained above 70% over 11 years of follow up ..read more
BioSpace » Biotechnology Industry News
2d ago
Cullinan Oncology, now renamed Cullinan Therapeutics, is riding the growing wave of interest in autoimmune disorders by refocusing its bispecific T cell-engager CLN-978 for systemic lupus erythematosus ..read more
BioSpace » Biotechnology Industry News
2d ago
On the heels of a Phase IIb win, Arrowhead Pharmaceuticals’ plozasiran could fulfill a critical unmet need in dyslipidemia treatment bringing in $707 million in sales by 2032, according to data analytics firm GlobalData ..read more
BioSpace » Biotechnology Industry News
2d ago
As its lead oral targeted protein degrader moves through Phase III in partnership with Pfizer, Arvinas signs a licensing deal handing over all rights and responsibilities to Novartis ..read more
BioSpace » Biotechnology Industry News
2d ago
Amylyx looks to the future after Relyvrio withdrawal, ADCs continue to attract investment and the drug shortage persists in the U.S ..read more
BioSpace » Biotechnology Industry News
2d ago
After withdrawing ALS drug Relyvrio from the U.S. and Canadian markets and laying off 70% of its workforce, the Cambridge, Mass.–based biopharma got a much-needed win in Wolfram syndrome ..read more
BioSpace » Biotechnology Industry News
2d ago
At this week’s American Academy of Neurology annual meeting, Amylyx provided additional data from its Phase III amyotrophic lateral sclerosis study showing the full extent of Relyvrio’s failure ..read more
BioSpace » Biotechnology Industry News
2d ago
Sage Therapeutics announced Wednesday it is scrapping its Parkinson’s disease program after the company’s investigational drug showed no benefit over placebo. Phase II studies of the oral treatment will continue in Huntington’s and Alzheimer’s diseases ..read more
BioSpace » Biotechnology Industry News
2d ago
With Wednesday’s readout showing symptom improvements in obstructive sleep apnea patients, Eli Lilly is preparing to file for a label expansion for its blockbuster weight-loss drug Zepbound ..read more
BioSpace » Biotechnology Industry News
1w ago
Following clearer overall survival data from the PSMAfore trial, Novartis on Thursday affirmed plans to file for a prostate cancer label expansion for its targeted radioligand therapy Pluvicto later this year ..read more